Emergent BioSolutions Inc. filed a Form 8-K with the SEC on November 2, 2026, announcing the release of its financial and operating results for the quarter ended September 30, 2026, along with a related conference call and earnings presentation materials.

Key Highlights

  • Filing date: November 2, 2026, covering the quarter ended September 30, 2026.
  • Exchange and ticker: Common Stock ($0.001 par value per share) listed on NYSE:EBS.
  • Press release: A press release announcing financial and operating results was issued on November 2, 2026, and furnished as Exhibit 99.1.
  • Earnings call: The company disclosed it would host a conference call on November 2, 2026, to discuss the quarterly results.
  • Presentation materials: Earnings Call Slides were furnished as Exhibit 99.2, dated November 2, 2026.
  • Signatory: The filing was signed by Richard S. Lindahl, Executive Vice President and Chief Financial Officer.

Emergent BioSolutions Furnishes Q3 2026 Earnings Materials Under Items 2.02 and 7.01

According to the filing, Emergent BioSolutions Inc., a Delaware-incorporated biopharmaceutical company headquartered at 300 Professional Drive, Gaithersburg, Maryland 20879, filed this Current Report under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). The company disclosed that it issued a press release on November 2, 2026, announcing its financial and operating results for the quarter ended September 30, 2026, which was furnished to the SEC as Exhibit 99.1.

Under Item 7.01, the filing states that the company planned to host a conference call on November 2, 2026, and that presentation materials described as Earnings Call Slides were prepared for use during that call, furnished as Exhibit 99.2. The filing notes that the content provided under Items 2.02 and 7.01, along with the attached exhibits, "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, as amended," and is not subject to the liabilities of that section unless expressly incorporated by reference in another filing.

The company's Common Stock carries a par value of $0.001 per share and trades on the New York Stock Exchange under the symbol EBS. The filing was signed on behalf of the registrant by Richard S. Lindahl in his capacity as Executive Vice President and Chief Financial Officer. No financial figures were included in the body of the 8-K itself; the actual results are contained in the furnished exhibits referenced above.

What Was Disclosed

Emergent BioSolutions Inc. filed a Form 8-K on November 2, 2026, to announce its third-quarter 2026 financial and operating results. The filing furnished a press release and earnings presentation slides as exhibits, and disclosed a related investor conference call held the same day.